Taxpayer-funded drugs must cost no more than in Canada, Europe
H.R. 10094 — Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2026 · Filed by Valerie Hoyle (D-OR) · 14 cosponsors · Introduced Aug 13, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires any company or researcher receiving federal funding for biomedical research to agree that the resulting drug, vaccine, device, or therapy will be priced reasonably—specifically, no higher than the median price charged in Canada and six other wealthy nations. The Secretary of HHS sets the pricing rules, can waive them if in the public interest, and requires companies to report clinical trial costs, federal subsidies, and annual revenues by county. The goal is to ensure taxpayers don't subsidize research only to pay inflated prices for the resulting products.
Why we flagged it
The bill's operative mechanism is a conditional requirement: companies receiving federal R&D funding must accept price caps indexed to international reference prices. It is not a direct price-setting mandate but a contractual condition tied to federal money, making it a leverage-based price control rather than a regulatory price ceiling.
What the text implies
- Companies may decline federal funding to avoid pricing obligations, potentially fragmenting publicly-funded research into private-only tracks and reducing transparency of taxpayer-supported innovation.
- The 'public interest' waiver standard is undefined and grants the Secretary broad discretion; political pressure or administrative capture could hollow the pricing requirement without legislative amendment.
The full analysis lists 5 implications of this text.
Who stands to gain
patients and consumers (lower drug prices); health insurers and public health programs (reduced reimbursement costs); state Medicaid programs (lower drug costs)